Trinity Biotech plc (TRIB)
NASDAQ: TRIB · Real-Time Price · USD
7.23
-0.04 (-0.55%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Trinity Biotech Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 43.79 | 43.79 | 61.56 | 56.83 | 62.52 | 81.15 |
Revenue Growth | -28.87% | -28.87% | 8.31% | -9.10% | -22.96% | -20.43% |
Gross Profit Gross Profit Growth | 16.89 | 16.89 | 21.44 | 19.45 | 17.27 | 33.45 |
Operating Income Operating Income Growth | -9.55 | -9.55 | -13.7 | -15.94 | -13.51 | 6.46 |
Net Income Net Income Growth | -37.38 | -37.38 | -31.79 | -24.02 | -41.01 | 0.88 |
Earnings Per Share EPS Growth | -60.36 | -60.36 | -60.96 | -94.13 | -182.34 | 6.28 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Clinical Laboratory Goods Clinical Laboratory Goods Growth | 31.68 | 31.68 | 39.37 | 42.29 | 46.04 |
Clinical Laboratory Services Clinical Laboratory Services Growth | 4.01 | 4.01 | 4.75 | 5.45 | 7.27 |
Point-Of-Care Products Point-Of-Care Products Growth | 8.1 | 8.1 | 17.43 | 9.09 | 9.21 |
Total Total Growth | 43.79 | 43.79 | 61.56 | 56.83 | 62.52 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 5.14 | 5.14 | 5.17 | 3.69 | 6.58 | 25.91 |
Total Debt Total Debt Growth | 137.98 | 137.98 | 100.76 | 67.43 | 72.2 | 99.16 |
Net Cash (Debt) Net Cash Growth | -132.85 | -132.85 | -95.6 | -63.74 | -65.62 | -73.25 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -214.55 | -214.55 | -159.69 | -249.78 | -291.78 | -525.65 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -5.93 | -5.93 | -4.19 | -11.56 | -0.92 | 13.24 |
Capital Expenditures CapEx Growth | -0.09 | -0.09 | -0.41 | -0.8 | -1.1 | -1.81 |
Free Cash Flow Free Cash Flow Growth | -6.02 | -6.02 | -4.6 | -12.36 | -2.02 | 11.43 |
Free Cash Flow Growth | - | - | - | - | - | -44.39% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 38.57% | 38.57% | 34.83% | 34.22% | 27.62% | 41.23% |
Operating Margin | -21.80% | -21.80% | -22.26% | -28.05% | -21.61% | 7.96% |
Pretax Margin | -84.91% | -84.91% | -49.92% | -64.98% | -70.02% | -2.37% |
Profit Margin | -85.36% | -85.36% | -51.64% | -42.26% | -65.59% | 1.08% |
FCF Margin | -13.74% | -13.74% | -7.47% | -21.75% | -3.23% | 14.08% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 34.16 |
Forward PE | - | 24.20 | 24.20 | 24.20 | 24.20 | 28.60 |
P/FCF Ratio | - | - | - | - | - | 2.62 |
PS Ratio | 0.13 | 0.34 | 0.25 | 0.29 | 0.60 | 0.37 |